Appropriate selection for omalizumab treatment in patients with severe asthma?

References

• Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention 2016. [ updated 2016]. Available from: http://www.ginasthma.org
   Google Scholar
• Reddel HK , Bateman ED , Becker A , et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):1–9.
   Web of Science ®Google Scholar
• Norman G , Faria R , Paton F , et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1–342.
   PubMed Web of Science ®Google Scholar
• Normansell R , Walker S , Milan SJ , et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:Cd003559.
   PubMed Web of Science ®Google Scholar
• Chung KF , Wenzel SE , Brozek JL , et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Fanta CH. Asthma. N Engl J Med. 2009;360(10):1002–1014.
   PubMed Web of Science ®Google Scholar
• Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386(9998):1086–1096.
   PubMed Web of Science ®Google Scholar
• Kuhl K , Hanania NA. Targeting IgE in asthma. Curr Opin Pulm Med. 2012;18(1):1–5.
   PubMed Web of Science ®Google Scholar
• Holgate S , Smith N , Massanari M , et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–1736.
   PubMed Web of Science ®Google Scholar
• Humbert M , Beasley R , Ayres J , et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Hanania NA , Alpan O , Hamilos DL , et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy a randomized trial. Ann Intern Med. 2011;154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ , Chen CW , Maykut R , et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151.
   PubMed Web of Science ®Google Scholar
• Statistics Denmark . [ cited 2015 Apr 30]. Available from: http://www.dst.dk.proxy1-bib.sdu.dk:2048/da/
   Google Scholar
• European Medicines Agency . [ cited 2015 May 20]. Available from: http://www.ema.europa.eu/ema/
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE) . Technology appraisal guidance 278: omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). 2013. Available from: https://www.nice.org.uk/guidance/ta278
   Google Scholar
• Danish Society of Respiratory Medicine . [ cited 2015 May 14]. Available from: http://www.lungemedicin.dk
   Google Scholar
• Bousquet J , Siergiejko Z , Swiebocka E , et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–678.
   PubMed Web of Science ®Google Scholar
• Davidsen JR , Hallas J , Sondergaard J , et al. Association between prescribing patterns of anti-asthmatic drugs and clinically uncontrolled asthma: a cross-sectional study. Pulm Pharmacol Ther. 2011;24(6):647–653.
   Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology . Guidelines for ATC classification and DDD assignment 2015. Oslo; 2014.
   Google Scholar
• Gaist D , Sorensen HT , Hallas J . The Danish prescription registries. Dan Med Bull. 1997;44(4):445–448.
   PubMedGoogle Scholar
• Schatz M , Kosinski M , Yarlas AS , et al. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124(4):719–723e1.
   PubMed Web of Science ®Google Scholar
• Kuo RN , Dong YH , Liu JP , et al. Predicting healthcare utilization using a pharmacy-based metric with the WHO’s anatomic therapeutic chemical algorithm. Med Care. 2011;49(11):1031–1039.
   Web of Science ®Google Scholar
• Skadhauge LR , Baelum J , Siersted HC , et al. [The occurrence of asthma among young adults. A population-based study in five west Danish counties]. Ugeskr Laeger. 2005;167(6):648–651.
   Google Scholar
• von Bulow A , Kriegbaum M , Backer V , et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2(6):759–767.
   PubMed Web of Science ®Google Scholar
• Apter AJ , Boston RC , George M , et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it’s not just black and white. J Allergy Clin Immunol. 2003;111(6):1219–1226.
   PubMed Web of Science ®Google Scholar
• Davidsen JR , Sondergaard J , Hallas J , et al. Impact of socioeconomic status on the use of inhaled corticosteroids in young adult asthmatics. Respir Med. 2011;105(5):683–690.
   PubMed Web of Science ®Google Scholar
• Buhl R , Marco AG , Cohen D , et al. Eligibility for treatment with omalizumab in Italy and Germany. Respir Med. 2014;108(1):50–56.
   Web of Science ®Google Scholar
• Sivapalan P , Lange P , Ulrik CS . [Obese asthma patients have poorer asthma control.]. Ugeskr Laeger. 2015;177(24):1146–1150.
   Google Scholar
• Hermosa JL , Sanchez CB , Rubio MC , et al. Factors associated with the control of severe asthma. J Asthma. 2010;47(2):124–130.
   PubMed Web of Science ®Google Scholar
• Lavoie KL , Bacon SL , Labrecque M , et al. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med. 2006;100(4):648–657.
   PubMed Web of Science ®Google Scholar
• Boulet LP , Franssen E . Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101(11):2240–2247.
   PubMed Web of Science ®Google Scholar
• Brusselle G , Michils A , Louis R , et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–1642.
   PubMed Web of Science ®Google Scholar
• Schumann C , Kropf C , Wibmer T , et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6(4):215–227.
   PubMed Web of Science ®Google Scholar
• Sorensen HT , Steffensen FH , Ejlersen E , et al. Research in the Danish health service system: completeness and validity of prescription data, illustrated by analysis of utilization of oral anticoagulants. Int J Risk Saf Med. 1995;7(1):33–41.
   Google Scholar
• Osterberg L , Blaschke T . Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar